Michael X Xu
President, Enantigen Therapeutics Inc., Pennsylvania Biotechnology Center
Dr Xu currently serves as Director of Medicinal Chemistry, Associate professor at the Institute for Hepatitis and Virus Research IHVR which was created by The Hepatitis B Foundation. He is President of Enantigen Therapeutics Inc a spinoff company of the IHVR which focuses on the development of oral therapeutics for the treatment of viral related diseases such as HBV, HCV, microbial infections including MDR pathogens and DENV at the Pennsylvania Biotechnology Center. Dr Xu is also Co-founder of Pharmabridge Inc., where he worked prior to joining IHVR. He was a medicinal chemist at Antimicrobial Agents Research Team at Johnson & Johnson Pharmaceutical Research & Development LLC. Dr Xu completed his PhD at New York University where he studied enantiosensors for chiral recognition.
Drug Discovery and Development, Structure Activity Relationship Study, Lead Optimization, Hepatitis B, Hepatitis C, Dengue Virus Infection, MDR pathogens.